Tango TherapeuticsTNGX
TNGX
About: Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Employees: 155
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
0.15% more ownership
Funds ownership: 99.09% [Q4 2024] → 99.24% (+0.15%) [Q1 2025]
11% less funds holding
Funds holding: 137 [Q4 2024] → 122 (-15) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]
47% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 30
55% less capital invested
Capital invested by funds: $329M [Q4 2024] → $147M (-$182M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for TNGX.
Financial journalist opinion
Based on 3 articles about TNGX published over the past 30 days
Positive
Zacks Investment Research
9 hours ago
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 day ago
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
2 weeks ago
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
Positive
Zacks Investment Research
1 month ago
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
GlobeNewsWire
2 months ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET.
Neutral
GlobeNewsWire
2 months ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.
Negative
Zacks Investment Research
2 months ago
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. “Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor,” said Barbara Weber, M.D.
Negative
Zacks Investment Research
2 months ago
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™